Case Study

Acute Lymphoblastic Leukemia
Case Study

LatticePoint provided extensive client support while the internal market access team was being built


  • Product was acquired by mid-sized pharma
  • Client had received pricing advice prior to LPC involvement
  • The product was being sold via EAPs in several markets across Europe prior to receiving EMA approval

LatticePoint Engagement

  • LatticePoint pricing strategy identified a commercial pricing increase relative to existing EAP priceWe developed the payer value proposition, global value dossiers and market entry strategy
  • Develop launch sequencing to optimize list prices across the EU to minimize reference pricing impact to revenue
  • Developed Health Economic models (cost-effectiveness, cost minimization, budget impact)
  • Developed and submitted reimbursement dossiers, including:
    • Reinforce evidence arguments via systematic literature reviews (SLRs), meta-analyses and indirect comparisons
    • Developed Health Economic models (cost-effectiveness, cost minimization, budget impact) tailored for each country

Team operated as in-country reimbursement leaders for preparation and negotiation with national customers. Client achieved quality access and pricing in each country.

We are happy to discuss how our approach can help your company.